MapMyGenome, a Hyderabad-based startup which provides unique, first-of-its kind “personal genomics” solutions to individuals, has today announced the closures of a Pre-Series A round from numerous investors.
MapMyGenome provides its diagnostics services via both offline and online channels. For its offline distribution, the startup has partnered with numerous hospitals across several cities. As of its online part, the startup provides its services via Snapdeal and Amazon India.
MapMyGenome is a unique startup in itself, and probably one of the very few rising names, when it comes to startups in the field of Bio-Tecch. Through its flagship product, Genomepatri™ , the startup provides predictive tests to know the status of an individual’s health, via his/her genome.
Anu Acharya, CEO, Mapmygenome, said,
This round of funding will help in scaling up our operations in India and globally. We are looking to expand our team (Leadership, Sales and marketing and genetic counseling network) where our focus is on quality of talent – education and expertise. We are also looking to invest in some assets and scale up our research.
The round involved multiple entrpreneurs and angel investors, including the likes of Rajan Anandan (MD- Google India), Arihant Patni –(MD at Hive Technologies) and Satveer Singh Thakral (CEO, Singapore Angel Network).
Personal genomics products provide insights into the genetic basis of individuals’ health, including traits, lifestyle, drug responses, inherited conditions, and diseases. By combining genetic report and health history with genetic counseling, Mapmygenome provides actionable steps for individuals and their physicians towards a healthier life.
MapMyGenome provides comprehensive predictive tests in diverse as well as complicated medical situations. The company has products spanning in several different categories, ranging from Breast Cancer detection, Brain wellness and Molecular Detection of illnesses like TB and other infectious diseases.
It also offers DNA Forensics, which includes maternity, paternity, sibling, and other identification tests.
The fresh round will be used to further scale up operations in more Indian cities, expand leadership team and scale up its products to a more global stage.